Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BCAC
Brookline Capital Acquisition
$2.95
$0.86
$9.50
$27.74
$19.90M-0.0339,682 shs29,998 shs
Cellectis S.A. stock logo
CLLS
Cellectis
$1.82
-5.7%
$1.53
$1.10
$2.43
$101.16M2.91150,982 shs133,053 shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$1.95
-3.0%
$2.68
$1.52
$16.94
$50.86M2.09688,459 shs168,792 shs
Surrozen, Inc. stock logo
SRZN
Surrozen
$8.48
-0.2%
$8.50
$5.90
$18.17
$72.61M0.5922,149 shs3,347 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BCAC
Brookline Capital Acquisition
0.00%0.00%0.00%0.00%-87.01%
Cellectis S.A. stock logo
CLLS
Cellectis
0.00%+14.47%+31.88%+25.52%-13.74%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
0.00%-8.45%-14.47%-49.74%-31.22%
Surrozen, Inc. stock logo
SRZN
Surrozen
0.00%-0.93%-14.34%-13.03%-9.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BCAC
Brookline Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
2.7787 of 5 stars
3.54.00.00.00.62.50.6
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
2.4066 of 5 stars
3.52.00.00.02.60.01.3
Surrozen, Inc. stock logo
SRZN
Surrozen
1.8427 of 5 stars
3.52.00.00.00.03.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BCAC
Brookline Capital Acquisition
0.00
N/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.00119.78% Upside
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.00
Buy$8.50335.90% Upside
Surrozen, Inc. stock logo
SRZN
Surrozen
3.00
Buy$38.50354.01% Upside

Current Analyst Ratings Breakdown

Latest BCAC, SNTI, CLLS, and SRZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
6/6/2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
Laidlaw
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/12/2025
Surrozen, Inc. stock logo
SRZN
Surrozen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
5/2/2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BCAC
Brookline Capital Acquisition
N/AN/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
$49.22M2.06N/AN/A$2.36 per share0.77
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$2.56M19.87N/AN/A$5.31 per share0.37
Surrozen, Inc. stock logo
SRZN
Surrozen
$10.65M6.82N/AN/A($6.55) per share-1.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BCAC
Brookline Capital Acquisition
-$480KN/A0.00N/AN/A-416.32%-4.75%N/A
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$52.79M-$10.84N/AN/AN/AN/A-177.24%-67.38%8/12/2025 (Estimated)
Surrozen, Inc. stock logo
SRZN
Surrozen
-$63.56M-$24.96N/AN/AN/AN/A-842.90%-71.32%8/11/2025 (Estimated)

Latest BCAC, SNTI, CLLS, and SRZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$0.58N/AN/AN/A$1.30 millionN/A
8/11/2025Q2 2025
Surrozen, Inc. stock logo
SRZN
Surrozen
-$1.23N/AN/AN/AN/AN/A
8/5/2025N/A
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.15N/AN/AN/A$10.07 millionN/A
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/9/2025Q1 2025
Surrozen, Inc. stock logo
SRZN
Surrozen
-$1.09-$3.13-$2.04-$7.43N/A$0.98 million
5/6/2025Q1 2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$0.56-$1.41-$0.85-$1.41$1.30 million$1.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BCAC
Brookline Capital Acquisition
N/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/AN/AN/AN/AN/A
Surrozen, Inc. stock logo
SRZN
Surrozen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BCAC
Brookline Capital Acquisition
N/A
0.07
0.07
Cellectis S.A. stock logo
CLLS
Cellectis
0.44
1.67
1.67
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/A
4.22
4.22
Surrozen, Inc. stock logo
SRZN
Surrozen
N/A
10.02
10.02

Institutional Ownership

CompanyInstitutional Ownership
BCAC
Brookline Capital Acquisition
51.83%
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
25.73%
Surrozen, Inc. stock logo
SRZN
Surrozen
66.57%

Insider Ownership

CompanyInsider Ownership
BCAC
Brookline Capital Acquisition
19.20%
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.12%
Surrozen, Inc. stock logo
SRZN
Surrozen
45.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
BCAC
Brookline Capital Acquisition
66.75 million5.45 millionNot Optionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
426.08 million25.27 millionNot Optionable
Surrozen, Inc. stock logo
SRZN
Surrozen
808.56 million4.69 millionNot Optionable

Recent News About These Companies

Surrozen (NASDAQ:SRZN) Stock Price Down 0.1% - Here's Why
Surrozen files to sell 5.21M shares of common stock for holders
Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year
Surrozen to focus Wnt expertise, technologies on ophthalmology programs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Brookline Capital Acquisition NASDAQ:BCAC

Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.82 -0.11 (-5.70%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.85 +0.03 (+1.65%)
As of 07/18/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Senti Biosciences stock logo

Senti Biosciences NASDAQ:SNTI

$1.95 -0.06 (-2.99%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.99 +0.04 (+2.05%)
As of 07/18/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Surrozen stock logo

Surrozen NASDAQ:SRZN

$8.48 -0.02 (-0.24%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$8.44 -0.04 (-0.47%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.